Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pralsetinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Optime Care Announces Enhanced Partnership with Rigel for GAVRETO® Patients
Details : The partnership aims to assist in the commercialization of Rigel Pharmaceuticals' approved product, Gavreto (pralsetinib), which is indicated for RET fusion-positive non-small cell lung cancer.
Product Name : Gavreto
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 27, 2024
Lead Product(s) : Pralsetinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Rigel Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership